Bluejay Therapeutics
Susanna Tan, MD, serves as the Senior Director of Clinical Development at Bluejay Therapeutics since October 2024. Previously, Susanna held the position of Director of Clinical Research - Respiratory at Vir Biotechnology, Inc. from November 2021 to October 2024, focusing on clinical development of monoclonal antibodies for respiratory viruses. From April 2019 to November 2021, Susanna worked as Director of Clinical Development in the Virology Therapeutic Area at Gilead Sciences, specializing in antivirals and immunomodulators for Hepatitis B. Susanna's academic background includes roles as an Instructor and Postdoctoral Fellow in Infectious Diseases at Stanford University School of Medicine from July 2013 to April 2019, and Chief Fellow in the same field. Earlier experience includes serving as Chief Resident and Resident Doctor in Internal Medicine at California Pacific Medical Center from July 2009 to June 2013. Education comprises an MD from Northwestern University - The Feinberg School of Medicine and a BA from Stanford University.
This person is not in any teams
Bluejay Therapeutics
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.